Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Emergent BioSolutions Inc. Common Stock (NY:EBS)

9.290 -0.600 (-6.07%)
Streaming Delayed Price Updated: 2:58 PM EST, Nov 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Emergent BioSolutions Inc. Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Reports Third Quarter 2025 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Releases New Survey Findings Revealing Heightened Concerns About Biological Threats and U.S. Preparedness
Policy opinion leaders believe a biological attack is both more likely and easier to execute than a nuclear strike, highlighting concerns around bioterrorism and the nation’s readiness to respond 
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions to Participate in Upcoming Investor Conferences
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Supports Voices for Awareness and Facing Fentanyl Now on August 21, 2025 for National Fentanyl Prevention and Awareness Day™
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Reports Second Quarter 2025 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
News headline image
New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox
Ongoing mpox outbreak continues to be a global health threat and is driving need for greater therapeutic research and innovation 
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate
Starting July 1, 2025, additional opioid overdose response tools will be available to continue addressing evolving patient and customer needs to combat public health crisis 
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Announces Addition to Russell 3000® Index
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Supports Victoria's Voice Foundation’s National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:PFE),(NASDAQ:COLL),(NYSE:TEVA),(NYSE:EBS) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
News headline image
Emergent BioSolutions to Participate in Upcoming Investor Conferences
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
From FN Media Group LLC
Via GlobeNewswire
News headline image
Emergent BioSolutions Reports First Quarter 2025 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health
Agreement will facilitate widespread distribution of NARCAN® Nasal Spray throughout Ontario 
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Announces Stock Repurchase Program
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08
From Emergent BioSolutions
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS